Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

MLA

Martin Gauthier, et al. “Prognostic Role of CD4 T-Cell Depletion after Frontline Fludarabine, Cyclophosphamide and Rituximab in Chronic Lymphocytic Leukaemia.” BMC Cancer, vol. 19, no. 1, Aug. 2019, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12885-019-5971-z.

APA

Martin Gauthier, Françoise Durrieu, Elodie Martin, Michael Peres, François Vergez, Thomas Filleron, Lucie Obéric, Fontanet Bijou, Anne Quillet Mary, & Loic Ysebaert. (2019). Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia. BMC Cancer, 19(1), 1–11. https://doi.org/10.1186/s12885-019-5971-z

Chicago

Martin Gauthier, Françoise Durrieu, Elodie Martin, Michael Peres, François Vergez, Thomas Filleron, Lucie Obéric, Fontanet Bijou, Anne Quillet Mary, and Loic Ysebaert. 2019. “Prognostic Role of CD4 T-Cell Depletion after Frontline Fludarabine, Cyclophosphamide and Rituximab in Chronic Lymphocytic Leukaemia.” BMC Cancer 19 (1): 1–11. doi:10.1186/s12885-019-5971-z.